SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

Carolina Covenant Documentary Wins Emmy
Chase Martin, assistant director of video for university development, and Jeyhoun Allebaugh, assistant director of photo and video for university development, accepted the best educational...
Wed Feb 25, 2026

When Every Second Counts: This UNC Device is Saving Lives
A breakthrough from UNC is helping frontline teams fight America’s drug crisis. Chemist Mike Ramsey’s research led to the MX908, a handheld mass spectrometer, that...
Sun Feb 22, 2026

Forbes Names Carolina to “Best Large Employer” List
The University of North Carolina is the top-ranked public institution in North Carolina on the Forbes 2026 Best Large Employer List released Tuesday. UNC is...
Sat Feb 21, 2026

For Tift Merritt, Time and Patience Have Made the Difference
Tift Merritt never thought she’d end up back in her hometown of Raleigh, North Carolina. For about 15 years she toured through America and Europe...
Sun Feb 15, 2026